Abstract: Purification of a poly(phenylene ether) includes contacting a liquid feed solution with a hydrated acidic clay adsorbent under conditions effective to provide a liquid effluent solution. The liquid feed solution includes a poly(phenylene ether), an organic acid impurity, and an amine impurity. The weight average molecular weight of the poly(phenylene ether) of the liquid effluent solution is within 1 percent of the weight average molecular weight of the poly(phenylene ether) of the feed solution, and the concentration of the amine impurity and the organic acid impurity of the liquid effluent solution is reduced by at least 40 percent relative to the concentration of the each impurity in the feed solution. Compositions and articles comprising a purified poly(phenylene ether) are also described.

Abstract: Purification of a poly(phenylene ether) includes contacting a liquid feed solution with a hydrated acidic clay adsorbent under conditions effective to provide a liquid effluent solution. The liquid feed solution includes a poly(phenylene ether), an organic acid impurity, and an amine impurity. The weight average molecular weight of the poly(phenylene ether) of the liquid effluent solution is within 1 percent of the weight average molecular weight of the poly(phenylene ether) of the feed solution, and the concentration of the amine impurity and the organic acid impurity of the liquid effluent solution is reduced by at least 40 percent relative to the concentration of the each impurity in the feed solution. Compositions and articles comprising a purified poly(phenylene ether) are also described.

Abstract: The present invention relates to a method of making compounds having affinity for the 1 A subtype of the serotonin receptor, i.e. 5HT1A. The method of the present invention provides advantages over the known methods of synthesis. The compounds obtained by the method of the invention have use in therapeutic methods. The compounds of the invention may also optionally compose a moiety suitable for detection by an in vivo imaging procedure and as such these compounds have use in in vivo imaging methods. The compounds have particular use in the treatment and diagnosis of various neurological and/or psychiatric disorders.

Abstract: Pyridazinone compounds of Formula I: (I) wherein: R? is alkyl or Ar, optionally substituted with at least one alkyl, halogen, hydroxyl, alkoxy, haloalkoxy, acid, ester, amino, nitro, amide, or alkoxyhalo; 2 R is independently alkyi, alkynyl, ester, amino, amide, acid, aryl, heteroaryl, aminoalkyl, —C(=0)alkyl, —C(=0)aryl, —C(=0)heteroaryl, —C(=0)heterocycloalkyl, —C(=0)heterocycloalkylAr, —C(=0)(CH2)nhalo, —C(?O)(CH2)nheterocyclyl, or —SC?Ar, optionally substituted with at least one alkyi, alkylhalo, halogen, nitro, aryl, heteroaryl, or heteroaryl(CH2)nhalo; R3 and R4 are independently hydrogen, alkyi, alkenyl, alkynyl, aryl, heteroaryl; Ar is an aryl, heteroaryl, cycloalkyl, heterocycloalkyl group; n is an integer from 0-10; or a radiolabeled derivative thereof. The compounds are useful as imaging probes of Tau pathology in Alzheimer's disease are described. Compositions and methods of making such compounds are also described.

Abstract: The present invention relates to radiodiagnostic compounds, methods of making those compounds, and methods of use thereof as imaging agents for preferably a HA serotonin 5-HT1A receptor for use in PET or SPECT, preferably PET. Compositions comprising an imaging-effective amount of radiolabeled compounds are also disclosed. The present invention also relates to non-radiolabeled compounds, methods of making those compounds, and methods of use thereof to treat various neurological and/or psychiatric disorders.